A pharmaceutical company has developed a new cancer treatment for pancreatic cancer, one of the most deadly diagnoses.The current 5 year survival rate for stage I pancreatic cancer is 15% with a population standard deviation of 2%, and the average 5 year survival of a SRS of 82 patients enrolled in a study sponsored by the company was 19%.

A)Using =.01, answer the question as to whether or not the new treatment is successful at increasing 5 year survival for pancreatic patients with a stage I diagnosis.

B)Interpret your results.

A) There is sufficient evidence based on a z statistic of 78.21 and a corresponding pvalue of <0.01 for the result assuming the null hypothesis is true.

B)The new drug has developed a candidate treatment that effectively lowers the survival time among patients with pancreatic cancer in this sample.

A) There is sufficient evidence based on a z statistic of 55.91 and a corresponding pvalue of <0.005 for the result assuming the alternative hypothesis is true.

B)The new drug hasnotdeveloped a candidate treatment that effectively increases the survival time among patients with pancreatic cancer in this sample.

A) There is sufficient evidence based on a z statistic of 18.11 and a corresponding pvalue of <0.0001 for the result assuming the null hypothesis is true.

B)The new drug has developed a candidate treatment that effectively increases the survival time among patients with pancreatic cancer in this sample.